Several other brokerages have also recently weighed in on DOVA. HC Wainwright reissued a buy rating and set a $18.00 price target on shares of Dova Pharmaceuticals in a research report on Friday, April 26th. JPMorgan Chase & Co. cut shares of Dova Pharmaceuticals from an overweight rating to an underweight rating and dropped their price target for the company from $34.00 to $20.00 in a research report on Wednesday, January 23rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. Dova Pharmaceuticals currently has a consensus rating of Hold and a consensus price target of $29.57.
Shares of DOVA opened at $10.76 on Tuesday. The firm has a market cap of $303.79 million, a price-to-earnings ratio of -4.14 and a beta of 2.06. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.46 and a quick ratio of 4.27. Dova Pharmaceuticals has a twelve month low of $5.62 and a twelve month high of $35.33.
In other news, Director Paul B. Manning purchased 68,000 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was acquired at an average price of $7.48 per share, with a total value of $508,640.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 60.30% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in DOVA. Vanguard Group Inc. lifted its position in shares of Dova Pharmaceuticals by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 619,604 shares of the company’s stock worth $12,993,000 after purchasing an additional 14,985 shares during the period. Broadfin Capital LLC purchased a new stake in shares of Dova Pharmaceuticals in the 4th quarter worth about $2,667,000. BlackRock Inc. lifted its position in shares of Dova Pharmaceuticals by 0.8% in the 3rd quarter. BlackRock Inc. now owns 1,154,232 shares of the company’s stock worth $24,204,000 after purchasing an additional 9,312 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Dova Pharmaceuticals by 14,705.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 5,034 shares of the company’s stock worth $38,000 after purchasing an additional 5,000 shares during the period. Finally, Sanders Morris Harris LLC purchased a new stake in shares of Dova Pharmaceuticals in the 1st quarter worth about $2,507,000. 31.17% of the stock is owned by institutional investors and hedge funds.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.
Featured Article: Certificate of Deposit (CD)
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.